

Investor Report

30 May 2025

Geiger Counter Limited

(the "Company")

Key Facts¹

Portfolio Managers	Keith Watson Robert Crayfourd		
Launch Date	July 2006		
Total Gross Assets	£62.4m		
Reference Currency	GBP		
Ordinary Shares	Net Asset Value: 42.51p Mid-Market Price: 40.00p		
Gearing	20.82%		
Premium / (Discount) to NAV	(5.90%)		
Ordinary Shares in Issue	121,447,742		
Ongoing Charge Ratio	2.11%		
Annual Management Fee 1.38%			
Bloomberg	GCL LN		
Sedol	B15FW330		
Year End	30 September		
Contact Information	CQSClientService@cqs m.com		
Company Broker	Cavendish Capital Markets Limited 020 7220 0500		
Annual Report and Accounts Published	December		
Investor Report	Monthly Factsheet		
Fiscal Year-End	30 September		
Results Announced	Finals: December Interims: June		

Sources

- 1 R&H Fund Services (Jersey) Limited, as at the last business day of the month indicated at the top of this report.
- 2 R&H Fund Services Limited/DataStream, as at the last business day of the month indicated at the top of this report, total return performance net of fees and expenses based on bid prices. These include historic returns and past performance is not a reliable indicator of future results. The value of investments can go down as well as up. Please read the important legal notice at the end of this document.
- 3 Market data sourced from Bloomberg unless otherwise stated. The Company may since have exited some or all of the positions detailed in the commentary.





Keith Watson and Robert CrayfourdPortfolio Managers

Description

The objective of Geiger Counter Limited is to provide investors with the potential for capital growth through investment primarily in the securities of companies involved in the exploration, development and production of energy, predominantly within the uranium investment portfolio may be invested in other resource-related companies from outside the energy sector.

Key Advantages for the Investor

- · Access to mining assets in the uranium sector
- May benefit from embedded subscription share
- Low correlation to major asset classes

Ordinary Share and NAV Performance²

	1 Month (%)	3 Months (%)	1 Year (%)	3 Years (%)	5 Years (%)
NAV	15.64	1.07	(41.40)	(9.57)	154.86
Share Price	18.34	1.01	(24.10)	(15.79)	133.92

Commentary³

The U₃O₈ (uranium) spot price closed the month up over 6.5% at \$75/lb while term prices remained little changed at \$80/lb. Related mining equities also performed well with the Company NAV rising 15.6%, largely in-line with the sterling return on the Junior Uranium Miners Index.

The introduction of four executive orders, signed by President Donald Trump on 23 May, helped lift sentiment towards the sector. The primary aim of these directives is to ensure the ramp-up in US nuclear generating capacity from 100 GW to 400 GW by 2050 and speed-up reactor deployment. The directives seek to prioritise the addition of 5GW of incremental power output via upgrades to existing nuclear reactors as well as commencing construction of an additional 10 new large-scale reactors by 2030. It is also notable that subsidies for other zero carbon forms of renewable energy generation may be scaled back, thus improving nuclear's competitive positioning in the US energy mix. Improved clarity on framework for future energy subsidies also helps remove uncertainty that may have contributed to the recent lack of utility buying activity.

Elsewhere, it was noticeable that other nuclear power-producing nations, including Taiwan, South Korea and Denmark, are seeking to reverse phase-out plans and actively add new capacity. In the case of Belgium, having previously delayed its phase out plans by 10 years following Russia's invasion of Ukraine and extended operating licenses by 20 years (to 2045) for 2 of its reactors, the government announced in May that it had dropped the phase out programme. Denmark also announced that it is reconsidering its 40-year ban on generating nuclear power. This followed on from news that Japan's Nuclear Regulatory Authority gave approval for the restart of reactor 3 at the Tomari nuclear facility, the 18th reactor to be awarded NRA clearance to restart. We believe all such news highlights the growing momentum behind nuclear power's inclusion in the global energy mix and the growing structural supply gap for uranium.

Utility inventories in established US and European markets are believed to be nearing minimum levels of around two years, close to the time it takes to mine, convert and enrich uranium, and then manufacture fuel rods. Utilities are therefore approaching a point when they will be required to re-engage in contracting having been relatively absent from the market since the panic buying in early 2024, after the Russian export ban was imposed. This improves confidence in the nearer-term outlook for uranium prices and may have prompted some pre-emptive carry trade activity which has helped close the wide price differential between the spot and term prices over the month.

Also relevant to the supply side outlook, state-owned uranium producer Kazatomprom continues to struggle with slower ramp-up of a new acid plant as it attempts to reduce its reliance on externally sourced acid supply. This is limiting its ability to increase output as evidenced by its slightly weaker-than-expected Q1 production.



Commentary³

The Nexgen made a strong contribution to the Company's performance with the share price rebounding 17% during May after recent subdued performance. Since month-end, the Saskatchewan State Government has provided strong support for development of Nexgen's core Rook I project. This is ahead of the two-part Federal Court hearing, scheduled to take place in November this year and February next. Additionally, the State governor announced approval for Nexgen to commence early infrastructure works ahead of the final federal court hearing decision, while also encouraging the Canadian Government to ensure the strategic project is prioritised as part of its "Major Federal Project" programme for development of critical minerals. Cameco also made a robust contribution with the share price a notable beneficiary of the US drive to commence construction of ten new large-scale reactors. The share price rose nearly 29% during May as a result. Exposure to both these equities was reduced in order to provide some liquidity flexibility for the Company. Some continued sterling strength provided a modest drag to performance.

AIFMD Leverage Limit Report (% NAV)

	Gross Leverage (%)²	Commitment Leverage (%) ³
Geiger Counter Limited	128	128

Top 5 Holdings (%)4

Name	(% of Gross Assets)
Nexgen Energy	26.0
Nexgen Energy Paladin Energy	12.8
UR-Energy	12.5
Cameco	7.2
IsoEnergy	5.7
Top 5 Holdings Represent	64.2

Sources:

- 1 Market data sourced from Bloomberg unless otherwise stated. The Company may since have exited some or all of the positions detailed in the commentary.
- 2 Manulife | CQS Investment Management, as at the last business day of the month indicated at the top of this report. For methodology details see Article 4(3) of Directive 2011/61/EU (AIFMD) and Articles 6, 7, 9 and 10 of Delegated Regulation 231/2013.
- 3 Manulife | CQS Investment Management, as at the last business day of the month indicated at the top of this report. For methodology details see Article 4(3) of Directive 2011/61/EU (AIFMD) and Articles 6, 8, 9, 10 and 11 of Delegated Regulation 231/2013.
- 4 R&H Fund Services (Jersey) Limited, as at the last business day of the month indicated at the top of this report. All holdings data are rounded to one decimal place. Total may differ to sum of constituents due to rounding.

The Company has announced the fifth Subscription Rights Price of 32.70 pence on 1 May 2025. The exercise date for the fourth Subscription Right is expected to be 30 April 2026.



Important Information

Manulife | CQS Investment Management is a trading name of CQS (UK) LLP which is authorised and regulated by the Financial Conduct Authority This document has been issued by CQS (UK) LLP and/or CQS (US), LLC which is a registered investment adviser with the US Securities and Exchange Commission, The term "CQS" or "Manulife | CQS Investment Management" as used herein may include one or more of CQS (UK) LLP, CQS (US), LLC or any other affiliated entity. The information is intended solely for sophisticated investors who are (a) professional investors as defined in Article 4 of the European Directive 2011/61/EU or (b) accredited investors (within the meaning given to such term in Regulation D under the U.S. Securities Act of 1933, as amended) and qualified purchasers (within the meaning given to such term in Section 2(a)(51) of the U.S Investment Company Act 1940, as amended). This document is not intended for distribution to, or use by, the public or any person or entity in any jurisdiction where such use is prohibited by law or regulation.

Manulife | CQS Investment Management is a wholly owned subsidiary of Manulife Investment Management (Europe) Limited.

This document is a marketing communication prepared for general information purposes only and has not been delivered for registration in any jurisdiction nor has its content been reviewed by any regulatory authority in any jurisdiction. The information contained herein does not constitute: (i) a binding legal agreement; (ii) legal, regulatory, tax, accounting or other advice; (iii) an offer, recommendation or solicitation to buy or sell shares or interests in any fund or investment vehicle managed or advised by CQS (a "CQS Fund") or any other security, commodity, financial instrument, or derivative; or (iv) an offer to enter into any other transaction whatsoever (each a "Transaction"). Any decision to enter into a Transaction should be based on your own independent investigation of the Transaction and appraisal of the risks, benefits and appropriateness of such Transaction in light of your circumstances. Any decision to enter into any Transaction should be based on the terms described in the relevant offering memorandum, prospectus or similar offering document, subscription document, key investor information document (where applicable), and constitutional documents and/or any other relevant document as appropriate (together, the "Offering Documents"). Any Transaction will be subject to the terms set out in the Offering Documents and all applicable laws and regulations. The Offering Documents supersede this document and any information contained herein. The Offering Documents for CQS UCITS range of funds is available here (https://www.cqs.com/ucits-funds#global-convertibles) in English (US persons will not be eligible to invest in CQS managed UCITS funds save to the extent set out in the relevant Offering Document). A copy of CQS' Complaints Policy, which sets out a summary of investors' rights, is available here (www.cqs.com/site-services/regulatory-disclosures) in English. CQS may terminate the arrangements for marketing or distribution of any CQS Fund at any time.

Nothing contained herein shall give rise to a partnership, joint venture or any fiduciary or equitable duties. The information contained herein is provided on a non-reliance basis, not warranted as to completeness or accuracy, and is subject to change without notice. Any information contained herein relating to any non-affiliated third party is the sole responsibility of such third party and has not been independently verified by CQS. The accuracy of data from third party vendors is not guaranteed. If such information is not

accurate, some of the conclusions reached or statements made may be adversely affected. CQS is not liable for any decisions made or action taken by you or others based on the contents of this document and neither CQS nor any of its directors, officers, employees or representatives accept any liability whatsoever for any errors or omissions or any loss howsoever arising from the use of this document.

Information contained in this document should not be viewed as indicative of future results as past performance of any Transaction is not indicative of future results. Any investment in a CQS Fund or any of its affiliates involves a high degree of risk, including the risk of loss of the entire amount invested. The value of investments can go down as well as up. Don't invest unless you're prepared to lose all the money you invest. This is a high-risk investment and you are unlikely to be protected if something goes wrong. Future performance is subject to taxation which depends on the personal situation of each investor and which may change in the future. Investments may lead to a financial loss if no guarantee on the capital is in place. An investment in any CQS Fund will involve a number of material risks which include, without limitation, risks associated with adverse market developments, currency and exchange rate risks, risk of counterparty or issuer default, and risk of illiquidity. Any assumptions, assessments, targets (including target returns and volatility targets), statements or other such views expressed herein (collectively "Statements") regarding future events and circumstances or that are forward looking in nature constitute CQS' subjective views or beliefs and involve inherent risk and uncertainties beyond CQS' control. Any indices included in this document are for illustrative purposes only and are not representative of CQS Funds in terms of either composition or risk (including volatility and other risk related factors). Unless stated to the contrary CQS Funds are not managed to a specific index.

The information contained herein is confidential and may be legally privileged and is intended for the exclusive use of the intended recipient(s) to which the document has been provided. In accepting receipt of the information transmitted you agree that you and/or your affiliates, partners, directors, officers and employees, as applicable, will keep all information strictly confidential. Any review, retransmission, dissemination or other use of, or taking of any action in reliance upon, this information is prohibited. Any distribution or reproduction of this document is not authorized and prohibited without the express written consent of CQS, or any of its affiliates. Unless otherwise stated to the contrary herein, CQS owns all intellectual property rights in this document.

PRI Note:

PRI is an investor initiative in partnership with UNEP Finance and the UN Global Compact. GMv12.

G1363070 / 06.25

London

4th Floor, One Strand, London WC2N 5HR, United Kingdom T: +44 (0) 20 7201 6900 | F: +44 (0) 20 7201 1200

New York

152 West 57th Street, 40th Floor, New York, NY 10019, US T: +1 212 259 2900 | F: +1 212 259 2699























